The pharma company had to scale vaccine production from 200 million annually to 3 billion at the pandemic's peak.

The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

Pfizer Inc. is doubling down on the booming weight-loss drug race, with CEO Albert Bourla declaring the company will be a "formidable competitor" after securing a $10 billion deal to acquire ...

A U.K. marketing watchdog has sanctioned Sanofi after ruling its CEO Paul Hudson may have undermined the U.K. government’s ...

Pfizer's CEO thinks his company will make big waves in the weight loss market. Eli Lilly does have a strong hold on the industry and won't let go anytime soon. Even so, Lilly could carve out a niche ...